The research team, based at Selcuk University’s Faculty of Veterinary Medicine, worked with ten male Akkaraman sheep aged eight to twelve months and weighing between 45 and 55 kilograms. The animals were housed under identical conditions with food and water available ad libitum, and the experimental protocol received approval from the university’s ethics committee. Each sheep received mefepronic acid by intramuscular injection into the gluteal muscles at 10 milligrams per kilogram once daily for three days, matching the dose and duration commonly used off-label in the field. Blood samples were drawn before the first injection and again at 24, 48 and 72 hours, allowing the researchers to track each animal against its own baseline in a repeated-measures, self-controlled design.

The analytical strategy was deliberately broad. Using sheep-specific ELISA kits and an autoanalyzer, the team measured a panel of oxidative stress markers: 8-hydroxy-2-deoxyguanosine, the most widely used biomarker of DNA damage from oxidative stress; malondialdehyde, a cytotoxic and mutagenic end product of lipid peroxidation; and the antioxidant enzymes superoxide dismutase, glutathione peroxidase and catalase. Cardiac injury was assessed through creatine kinase-MB isoenzyme and troponin I, while liver and bile duct status was tracked via alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and total bilirubin. Kidney function was gauged by blood urea nitrogen and creatinine, and lipid metabolism by cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein. Data were tested for normality with the Shapiro-Wilk test, log-transformed where necessary, and analysed with repeated measures ANOVA and Bonferroni post-hoc comparisons.

Clinically, the drug was uneventful. None of the sheep developed fever, shivering, salivation or any other observable adverse reaction over the three-day monitoring window. Beneath that calm surface, however, the serum chemistry told a more nuanced story. Levels of 8-OHdG rose significantly at 24 hours, climbing from a baseline of roughly 4.86 nanograms per millilitre to 7.37, before drifting back toward starting values by 72 hours. Catalase activity, by contrast, declined significantly by the end of the study, falling from 4.22 to 3.02 nanograms per millilitre. Malondialdehyde, superoxide dismutase and glutathione peroxidase all fluctuated without reaching statistical significance, and the authors note that the isolated 8-OHdG spike, unaccompanied by changes in the other oxidative markers, cannot be directly interpreted as genuine DNA damage.

The cardiac findings followed a similar pattern of transient change without clear pathology. Creatine kinase-MB isoenzyme levels jumped significantly at 24 hours, from 0.62 to 1.01 nanograms per millilitre, then returned to near-baseline values. Troponin I, the more cardiospecific biomarker that has largely displaced CK-MB in clinical practice because of its superior specificity for heart muscle, showed no significant change at any time point. The authors place this result in context by explaining that CK-MB is a sensitive but nonspecific marker: it is produced predominantly in cardiac muscle but also in small amounts in the uterus, small intestine, diaphragm, tongue and prostate, and its rapid clearance from circulating blood has historically limited its diagnostic value. Given that troponin I remained stable, the team concluded that no clinically significant myocardial damage occurred during the short observation period.

Kidney and lipid parameters produced the study’s most intriguing metabolic signals. Blood urea nitrogen fell significantly by 72 hours, from 11.31 to 9.01 milligrams per decilitre, though the decline stayed within published reference ranges for sheep and serum creatinine, the more reliable indicator of glomerular filtration rate, remained unchanged throughout. High-density lipoprotein dropped significantly by 72 hours and low-density lipoprotein fell significantly at both 24 and 72 hours, the latter sliding from 27.50 to 19.00 milligrams per decilitre. Cholesterol and triglycerides also trended downward without reaching significance. The authors suggest these lipid shifts are consistent with the drug’s known metabolic activity and may even underpin its reported benefits in fatty liver syndrome, where reducing circulating lipid load could ease the burden on an already compromised liver.

Liver markers were similarly unremarkable. Alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and total bilirubin all showed nonsignificant decreases over the study period, a direction of change that fits comfortably with the drug’s intended choleretic action rather than suggesting hepatocellular injury. This aligns with earlier reports in other species: mefepronic acid given to dairy cows before and after calving had no adverse effect on serum lipid parameters and appeared to improve postpartum liver function, and the compound has been used as supportive therapy in dogs with hepatopathy. Rat studies have also reported a limited protective effect against hepatic steatosis, and off-label use in sheep has been credited with helping correct the severe metabolic liver dysfunction associated with liver fluke infection when combined with triclabendazole and levamisole.

The study’s design choices carry both strengths and constraints that shape how the results should be read. The self-controlled, repeated-measures framework meant each animal served as its own reference, which the authors argue reduced the noise introduced by inter-individual biological variation and allowed clean tracking of time-dependent changes after dosing. But the absence of a separate control group means drug-related effects cannot be fully disentangled from spontaneous or time-dependent physiological drift. The sample of ten healthy male sheep, monitored for only 72 hours, further limits generalisation. The authors are explicit that these are preliminary data, and they flag particular caution for animals with pre-existing heart disease or other risk factors, where the transient CK-MB elevation and catalase decline could behave differently.

Species-specific idiosyncrasies in drug safety provide a compelling rationale for the work. Tilmicosin, a macrolide antibiotic considered safe in cattle, has been reported to cause mortality in goats. Ivermectin, a mainstay antiparasitic that is generally well tolerated in dogs, produces toxicity and death in Collies carrying the MDR1 mutation. Against that backdrop, assuming that a drug proven safe in five target species will behave identically in a sixth is clearly untenable. The oxidative stress angle added further urgency: prior work in dairy cattle suggested mefepronic acid can reduce lipid peroxidation in hepatocytes, and researchers have proposed that the drug, alone or with ammonium molybdate, might help in copper poisoning cases in sheep, making it important to know whether the compound itself provokes oxidative damage at therapeutic doses.

The overall verdict is one of conditional reassurance. In healthy sheep at the standard 10 milligrams per kilogram intramuscular dose for three days, mefepronic acid caused no clinical adverse effects, no clinically significant disturbance of liver or kidney function, and no evidence of myocardial injury by the most specific available biomarker. The transient 8-OHdG rise, catalase fall and CK-MB bump are best interpreted as subclinical, self-resolving fluctuations rather than signs of organ damage, though the authors caution that such effects could prove more pronounced in sick, pregnant or otherwise compromised animals. They call for future studies in different breeds and in diseased or pregnant sheep to establish whether the drug’s growing off-label repertoire in ovine medicine, from fertility support to metabolic disease, can rest on firmer safety ground. For now, the message to practitioners is measured: the drug appears tolerable in healthy ewes and rams, but risk groups deserve closer monitoring.

Subject of Research: Safety and biochemical effects of extra-label mefepronic acid administration in sheep

Article Title: Safety Assessment of Mefepronic Acid in Sheep

Article References: Canbar, R., Parlak, T. M., Uslu, M., & Yazar, E. (2026). Safety Assessment of Mefepronic Acid in Sheep. Veterinary Medicine and Science, 12(5), Article e71236. https://doi.org/10.1002/vms3.71236

Image Credits: AI Generated

DOI: 10.1002/vms3.71236

Keywords: mefepronic acid, sheep, veterinary pharmacology, oxidative stress, choleretic, cardiac biomarkers, CK-MB, troponin I, liver function, kidney function, lipid metabolism, drug safety

The retracted review concerned a class of pollutants with genuine toxicological importance. Polycyclic aromatic hydrocarbons, often abbreviated PAHs, are a large family of organic compounds composed of fused aromatic rings. They form whenever organic material is incompletely burned, which means that the dominant human exposure routes include tobacco smoke, charred and grilled food, wood and coal combustion, vehicle exhaust, and a wide range of occupational settings such as asphalt paving, coking, and aluminum smelting. Because many PAHs are lipophilic and are metabolized in the liver, the organ is both the principal site of their biotransformation and a plausible target for their toxic effects. Enzymes of the cytochrome P450 family convert parent PAHs into reactive metabolites, some of which form DNA adducts and protein adducts, generate oxidative stress, and can disturb hepatocellular function. Serum markers such as alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase are therefore commonly used in environmental epidemiology as indirect indicators of liver injury in populations exposed to air pollution.

Against that background, a systematic review of observational studies examining PAH exposure and liver function would have been a useful contribution, since observational evidence in this field is scattered across occupational cohorts, general-population surveys, and studies using biomarkers of internal dose such as urinary hydroxylated PAH metabolites. The retraction does not establish that the underlying hypothesis is wrong; rather, it removes this particular synthesis from the citable literature because the journal can no longer vouch for its integrity. That distinction matters for readers who encounter the paper through search engines or reference managers: the retraction notice is now attached to the article record, and the canonical digital object identifier for the notice itself is 10.1007/s11869-026-02101-6, while the original article was published under a different identifier in 2023.

The first ground for retraction, substantial overlap with a previously published article, points to one of the most closely watched problems in contemporary scholarly publishing. Textual and data overlap between papers can range from redundant publication, in which the same work is submitted to multiple journals, to outright plagiarism, in which text or findings are reused without attribution. In this case, the journal identified the overlapping publication as a paper that itself has since been retracted: a systematic review on the association between prenatal exposure to polycyclic aromatic hydrocarbons and childhood intelligence, published in Environmental Science and Pollution Research in 2023, which the notice explicitly labels as a retracted article. Two authors were common to both papers. The fact that the companion article was also retracted suggests a broader pattern in which a cluster of related manuscripts, produced by large and geographically dispersed author teams, came under editorial scrutiny at more than one journal.

The second ground, that multiple references appeared to be irrelevant, is a hallmark that research-integrity specialists associate with certain forms of coordinated manuscript production. Citation manipulation, whether intended to inflate the metrics of particular journals or authors, or simply the byproduct of template-driven writing, undermines the scholarly function of a reference list, which is supposed to document the evidentiary basis of a review’s claims. In a systematic review, where the entire contribution depends on the transparent identification, screening, and synthesis of primary studies, irrelevant citations are not a cosmetic flaw. They make it impossible for readers to verify which studies were actually considered, how inclusion and exclusion criteria were applied, and whether the pooled conclusions follow from the evidence. When such problems surface and authors decline to engage with the journal, editors are left with little alternative to retraction.

The authorship pattern of the retracted paper is itself noteworthy. The article listed authors affiliated with institutions in Indonesia, Saudi Arabia, Russia, Iraq, India, Colombia, Poland, Yemen, Uzbekistan, and Iran, a span of countries that would be unusual for a review of environmental health data focused on any single population. Large, internationally scattered author lists with limited apparent connection to the study subject have become a recognized red flag in the wave of retractions that has swept through the scientific literature in recent years, particularly among papers produced by commercial paper mills. Publication ethics watchdogs and major publishers have documented tens of thousands of retractions in recent years, a substantial fraction of them linked to systematic manipulation of the publishing pipeline rather than to honest error. While the retraction notice in this case does not allege paper-mill involvement, the combination of overlapping text, irrelevant references, and non-response from a dozen or more authors fits a familiar profile.

The non-response of the authors is a significant procedural element. Journals typically follow a due-process protocol when integrity concerns arise: they contact the corresponding authors, describe the concerns, and invite an explanation or rebuttal, sometimes allowing weeks or months for a reply. When authors engage, the outcome may be a correction, an expression of concern, or, if the explanation is unsatisfactory, retraction. When authors do not respond at all, editors must weigh the harm of leaving a flawed paper in the literature against the fairness of acting without the authors’ side of the story. In this instance the Editor-in-Chief concluded that the evidence of overlap and citation problems, combined with the authors’ silence, justified withdrawal of the article and a public statement that confidence in the work could no longer be maintained. The notice also records that none of the authors responded to the publisher’s correspondence about the retraction itself.

For the environmental health community, the retraction carries practical consequences. Systematic reviews are frequently cited in risk assessments, in the design of subsequent studies, and in policy documents that summarize the state of the evidence on pollutant-health associations. A retracted review on PAHs and liver function cannot be used as a summary of that evidence, and researchers citing the field should rely on the primary observational studies and on reviews that have survived editorial scrutiny. At the same time, the underlying scientific question remains open and legitimate. Epidemiologists continue to investigate whether chronic low-level PAH exposure, as measured by urinary metabolites or by proxies such as traffic-related air pollution, is associated with altered liver enzymes, non-alcoholic fatty liver disease, or other hepatic outcomes. Well-conducted reviews that document their search strategies, register their protocols, and report their screening decisions transparently remain the right tool for answering that question.

The episode also illustrates the machinery of post-publication correction that major publishers now deploy. The retraction notice is linked to the article record through the CrossMark service, which allows readers checking a document to verify whether they are viewing the current, authoritative version. The notice identifies the journal, the volume and article number, the publication date, and the relationship to the original paper, and it cites the retracted companion article explicitly so that readers can trace the overlap. This apparatus does not erase the flawed paper from databases, since retracted articles remain online with their notices attached; that permanence is deliberate, preserving the scholarly record while warning readers away from relying on the content. It also creates a public trail that institutions can consult when evaluating the output of researchers involved in retractions.

Ultimately, the case is a reminder that the credibility of environmental health science depends as much on the integrity of synthesis as on the quality of the underlying measurements. Air pollution research has produced some of the most consequential public health findings of the past decades, linking fine particulate matter, nitrogen dioxide, and combustion byproducts to cardiovascular, respiratory, and metabolic disease, and PAHs remain a plausible contributor to hepatic toxicity given their metabolism in the liver and their capacity to form reactive adducts. But every meta-analytic claim inherits the weaknesses of the papers it aggregates, and a review built on irrelevant citations and duplicated material cannot support confident conclusions. The retraction of this systematic review removes a compromised summary from the literature, flags a cluster of related concerns across at least two journals, and underscores the growing vigilance of editors and integrity researchers toward the patterns of overlap, citation manipulation, and authorial silence that have come to define the current era of scholarly self-correction.

Subject of Research: Retraction of a systematic review on polycyclic aromatic hydrocarbon exposure and liver function due to article overlap and citation integrity concerns

Article Title: Retraction Note: Exposure to polycyclic aromatic hydrocarbons and liver function: a systematic review of observational studies

Article References: Retraction Note: Exposure to polycyclic aromatic hydrocarbons and liver function: a systematic review of observational studies. (n.d.). https://doi.org/10.1007/s11869-026-02101-6

Image Credits: AI Generated

DOI: 10.1007/s11869-026-02101-6

Keywords: retraction, polycyclic aromatic hydrocarbons, liver function, systematic review, research integrity, Air Quality Atmosphere & Health, citation manipulation, environmental health, hepatotoxicity, air pollution, Springer Nature, publishing ethics

The research, led by a team at Beijing Children’s Hospital of Capital Medical University, analyzed data from 257 pediatric patients treated with sirolimus, drawing on a remarkable 766 to 892 blood samples collected during routine care. Rather than treating adverse reactions as isolated events, the investigators systematically quantified the relationship between steady-state trough concentrations of sirolimus, known as Cmin, and three of the drug’s most clinically significant toxicities: myelosuppression, abnormal liver function, and dyslipidemia. Trough concentrations, measured immediately before the next dose, are the standard metric for therapeutic drug monitoring of sirolimus, because the drug’s effects and toxicities track closely with whole-blood levels.

What makes the study methodologically distinctive is its pairing of two computational approaches that rarely meet in pharmacology. The first is Bayesian kernel machine regression, or BKMR, a flexible statistical framework originally developed to assess the health effects of complex environmental exposures such as air pollutant mixtures. BKMR excels at modeling nonlinear relationships and interactions among multiple simultaneous exposures without imposing rigid functional forms, which makes it well suited to the messy reality of pediatric drug monitoring, where age, weight, disease type, concomitant medications, and treatment duration all shift the toxicity landscape. The second component is a population pharmacokinetic model, or PopPK, which describes how sirolimus is absorbed, distributed, and cleared across a heterogeneous population of children and predicts individual exposure from dosing history and patient characteristics.

By integrating the two into a unified BKMR-PopPK framework, the researchers created something more powerful than either method alone. The PopPK model translates a proposed dose into a predicted trough concentration for a specific child, while the BKMR layer converts that predicted exposure into a quantified risk of myelosuppression, liver injury, or dyslipidemia. The result is a tool for model-informed precision dosing, an approach that replaces one-size-fits-all weight-based dosing with individualized regimens designed to keep each patient inside a safety window that is narrow enough to prevent toxicity but wide enough to control the underlying vascular lesion.

The analysis identified disease complexity and duration of therapy as key modifiers of risk. Children with complex or mixed vascular malformations faced different exposure-response relationships than those with simpler, more localized lesions, and the risks of certain toxicities grew as treatment extended over months. Based on these quantitative relationships, the team recommends routine trough concentration monitoring within two distinct safety windows: 5.0 to 7.5 nanograms per milliliter for children with simple lesions or milder disease, and 8.0 to 10.2 nanograms per milliliter for those with complex or mixed vascular malformations, who may require higher exposure to achieve disease control.

The temporal dimension of the findings carries particular weight for families and clinicians committed to long-term therapy. Sirolimus treatment for vascular anomalies often continues for a year or more, and the study’s results indicate that vigilance must intensify rather than relax as months accumulate. Beyond six months of treatment, the authors call for heightened surveillance for myelosuppression and dyslipidemia through regular screening of blood counts and lipid panels. This is a meaningful departure from practice patterns in which monitoring may become less rigorous once a patient has tolerated the drug through the early treatment period.

Each of the three adverse reactions examined carries its own clinical stakes. Myelosuppression, the suppression of bone marrow activity, can lower blood cell counts and increase vulnerability to infection, anemia, and bleeding. Abnormal liver function signals hepatotoxicity that, if unchecked, can progress to more serious injury. Dyslipidemia, the elevation of blood lipids, is subtler but consequential in children, because lipid abnormalities established early in life can seed long-term cardiovascular risk. By quantifying how each toxicity relates to trough concentration, the framework allows clinicians to weigh these distinct risks against the therapeutic benefit of suppressing the malformation itself.

The broader significance of the work extends beyond vascular anomalies. Rare pediatric diseases pose a persistent methodological dilemma: patient populations are small, clinical trials are difficult to mount, and safety data are often fragmentary or anecdotal. The authors argue that their integrated framework offers a template for extracting rigorous, quantitative safety insights from the routine clinical data that even small cohorts generate. In doing so, the study addresses a genuine knowledge gap. Prior research had suggested a strong link between sirolimus exposure and adverse reactions, but the quantitative relationship, the actual probabilities of toxicity at given concentrations, had remained undefined, leaving clinicians to rely on empirical dosing inherited from transplant medicine.

Therapeutic drug monitoring itself is not new to sirolimus; the drug’s narrow therapeutic index has long demanded blood level measurement. What is new is the precision with which those measurements can now be interpreted. Instead of a single broad target range applied to every child, the study supports disease-specific and time-dependent target ranges, embedded within a predictive model that can forecast an individual patient’s exposure and toxicity risk before a dose is even administered. The retrospective design, approved by the Institutional Ethics Committee of Beijing Children’s Hospital, means the findings will need prospective validation, but the sample size and the density of pharmacokinetic sampling lend the conclusions substantial credibility.

For the children who depend on sirolimus to shrink lesions that compress airways, deform faces, or bleed unpredictably, the study promises something deceptively simple: a better chance of staying on the drug long enough for it to work. Treatment discontinuation driven by adverse reactions is one of the most common reasons vascular anomaly therapy fails, and every avoidable discontinuation represents a child whose disease resumes its advance. By converting pharmacological data into individualized risk estimates and dosing guidance, the BKMR-PopPK framework moves pediatric vascular anomaly care a decisive step closer to the era of precision medicine, where the question is no longer simply how much drug to give, but how much drug this particular child can safely carry.

Subject of Research: Quantifying sirolimus exposure-response safety relationships in pediatric vascular anomalies using an integrated BKMR-PopPK framework

Article Title: Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing

Article References: Liu, B., Xu, X.-L., Wang, J.-L., Li, J., Wu, Y.-X., Zhang, X.-X., Liu, Q.-Y., Zhao, Y.-M., Guo, P., Zhang, R.-Q., Zhou, H., Mao, X.-T., Jia, Y.-M., Cheng, X.-L., Wang, S.-C., & Wang, X.-L. (2026). Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01076-9

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01076-9

Keywords: sirolimus, vascular anomalies, pediatrics, adverse drug reactions, therapeutic drug monitoring, population pharmacokinetics, Bayesian kernel machine regression, precision dosing, myelosuppression, dyslipidemia, liver function, rare diseases

The research, led by Lubin Gou and Junqiang Lei of the First Hospital of Lanzhou University and Lanzhou University’s First Clinical Medical College, focused on patients with liver cirrhosis without overt hepatic encephalopathy, a stage abbreviated LC-nOHE. This is the window in which the disease has already compromised liver function but has not yet produced the confusion, disorientation, and personality changes that define overt hepatic encephalopathy. Understanding what happens in the brain during this silent phase is critical, because it may reveal the earliest opportunities for intervention before irreversible damage takes hold.

The team recruited 86 patients with liver cirrhosis but no overt encephalopathy, along with 62 healthy controls, and acquired high-resolution three-dimensional T1-weighted magnetic resonance images of every participant’s brain. From these scans, the researchers extracted the volume of the thalamus and three distinct measures of cortical shape: cortical thickness, sulcal depth, and fractal dimension, a measure of the complexity of the brain’s folded surface. Rather than examining these features in isolation, the investigators constructed structural covariance networks, mathematical maps in which brain regions are connected if their anatomical features covary across individuals. Such networks are widely used as proxies for coordinated maturational and degenerative processes, offering a window into how brain regions change together as a system.

The results were striking at multiple levels. Compared with healthy controls, patients with cirrhosis showed enlargement of the thalamus alongside a broad range of cortical morphological abnormalities. At the level of whole-network organization, the thalamo-cortical structural covariance networks of patients displayed reduced segregation, meaning the brain’s specialized modules were less clearly differentiated, and decreased integration, meaning efficient communication across the network was impaired. These two properties, segregation and integration, are hallmarks of a healthy, well-organized brain, and their simultaneous deterioration suggests a fundamental disruption of the architecture that supports cognition.

Zooming in on individual network nodes, the researchers found that the centrality of three regions was significantly reduced in patients: the thalamus itself, the supramarginal gyrus, and the insula. Each of these regions plays a recognizable role in the syndrome. The thalamus relays sensory and motor signals to the cortex and regulates consciousness and alertness; the supramarginal gyrus contributes to language and spatial cognition; and the insula supports interoception and awareness of the body’s internal state. Reduced centrality in these hubs indicates that they had lost influence within the network, becoming less connected to the rest of the brain’s structural architecture.

Perhaps the most clinically significant finding was the relationship between brain changes and liver function. The degree centrality of the thalamus was negatively correlated with liver function measures, meaning that the worse the liver was performing, the more the thalamus had lost its position within the brain’s structural network. This correlation ties the brain imaging directly to the severity of liver disease and supports the idea that the thalamus sits at the front line of the liver-brain axis, the pathway by which hepatic dysfunction, circulating toxins such as ammonia, and systemic inflammation are translated into neural injury.

To move beyond correlation and probe causality, the team applied a technique called causal analysis of structural covariance networks, or CaSCN. This approach examines how changes in one brain region’s morphology relate to changes in others across the progression of disease, allowing researchers to ask which region leads and which follows. The analyses demonstrated that thalamus volume had causal effects on the alterations of cortical morphology as liver dysfunction progressed. In other words, the data are consistent with a model in which the thalamus is not merely another victim of cirrhosis but an active driver, propagating structural changes outward to the cortical regions with which it is connected.

The study then took an unusual additional step: linking the brain imaging to genomics through imaging transcriptomics. Using normative gene-expression profiles from the Allen Human Brain Atlas, the researchers evaluated whether the spatial pattern of causal effects across the cortex overlapped with the spatial distribution of specific genes. It did. The pattern of causal path coefficients was spatially correlated with the expression of particular genes in the normative atlas, suggesting that the cortical regions most vulnerable to thalamus-driven change are also those with distinctive molecular signatures. Gene ontology analyses pointed toward enrichment in biological processes, molecular functions, and cellular components that may help explain why some cortical areas are preferentially affected while others are relatively spared.

Taken together, the findings provide a comprehensive, multilevel view of how the thalamo-cortical circuit becomes progressively vulnerable in liver cirrhosis before overt encephalopathy appears. The enlargement of the thalamus, consistent with processes such as edema or glial changes reported in prior literature on hepatic encephalopathy, appears to initiate a cascade that erodes the segregation and integration of the entire structural network, strips key hubs of their centrality, and reshapes the cortex in patterns governed partly by underlying gene expression. Because the thalamus’s network position tracks liver function, measures of thalamo-cortical network integrity could potentially serve as imaging biomarkers for identifying patients at risk of progressing to overt hepatic encephalopathy, enabling earlier monitoring and treatment.

The authors emphasize that these findings offer a potential mechanism-driven framework for understanding the earliest brain consequences of liver disease, one that connects organ function, network neuroscience, and transcriptomics within a single analytical pipeline. The work was supported by the Lanzhou University First Affiliated Hospital Foundation and the Science and Technology Department of Gansu Province, and it was approved by the Institutional Ethics Committee of the First Hospital of Lanzhou University. As cirrhosis continues to affect millions worldwide, studies like this one bring clinicians closer to detecting, and perhaps preventing, the neurological toll of liver disease before it announces itself in the clinic.

Subject of Research: Structural covariance network alterations of the thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy

Article Title: Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics

Article References: Gou, L., Ren, H., Xu, W., Gao, Y., Wang, S., Zhang, Y., Dou, Y., & Lei, J. (2026). Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02790-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02790-6

Keywords: liver cirrhosis, hepatic encephalopathy, thalamus, thalamo-cortical circuit, structural covariance network, MRI, liver-brain axis, imaging transcriptomics, cortical thickness, liver function, neuroimaging, Allen Human Brain Atlas